InvestSMART

Percheron Therapeutics Limited (ASX: PER) - Announcements

- Current share price for PER : $0.003

ASX company news and announcements for Percheron Therapeutics Limited (PER) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Percheron Therapeutics Limited (PER) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Percheron Therapeutics Limited (PER), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Percheron Therapeutics Limited (PER)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$5 Notification of cessation of securities - PER 11 Mar 2025 3:13PM $0.010 $0.003 fallen by 70%
$5 Response to ASX Query 6 Mar 2025 11:52AM $0.011 $0.003 fallen by 72.73%
$5 Ceasing to be a substantial holder 6 Mar 2025 9:50AM $0.011 $0.003 fallen by 72.73%
$5 Results of General Meeting 4 Mar 2025 12:13PM $0.010 $0.003 fallen by 70%
$5 Change of Director's Interest Notice - Dr James Garner 26 Feb 2025 4:26PM $0.013 $0.003 fallen by 76.92%
$5 Notices received under S203D and S249D of Corporations Act 25 Feb 2025 9:59AM $0.013 $0.003 fallen by 76.92%
$5 Update on Partnering Progress 24 Feb 2025 8:01AM $0.013 $0.003 fallen by 76.92%
$5 Change of Interest of Substantial Holder from PVL 21 Feb 2025 3:22PM $0.013 $0.003 fallen by 76.92%
$5 Letter From The Chair and Half Year Accounts 19 Feb 2025 11:30AM $0.009 $0.003 fallen by 64.71%
$5 Percheron Makes Rapid Progress in Partnering Discussions 12 Feb 2025 8:19AM $0.008 $0.003 fallen by 62.50%
$5 Webinar Presentation - Phase IIb study of avicursen 6 Feb 2025 8:26AM $0.008 $0.003 fallen by 62.50%
$5 Notification of cessation of securities - PER 3 Feb 2025 3:56PM $0.009 $0.003 fallen by 64.71%
$5 Quarterly Activities Report and Appendix 4C 31 Jan 2025 8:41AM $0.008 $0.003 fallen by 62.50%
$5 Notice of General Meeting 24 Jan 2025 8:36AM $0.009 $0.003 fallen by 66.67%
$5 Change of Interest of Substantial Holder from PVL 17 Jan 2025 9:08AM $0.008 $0.003 fallen by 62.50%
$5 Becoming a substantial holder 7 Jan 2025 11:53AM $0.009 $0.003 fallen by 66.67%
$5 Notices received under s203D and s249D of Corporations Act 7 Jan 2025 8:19AM $0.009 $0.003 fallen by 66.67%
$5 Becoming a substantial holder from PVL 6 Jan 2025 1:00PM $0.010 $0.003 fallen by 68.42%
$5 Letter to Percheron Therapeutics Limited Shareholders 6 Jan 2025 8:28AM $0.009 $0.003 fallen by 66.67%
$5 Change of Director's Interest Notice-Dr Charmaine Gittleson 31 Dec 2024 11:39AM $0.008 $0.003 fallen by 62.50%
$5 Change of Director's Interest Notice - Dr James Garner 27 Dec 2024 8:27AM $0.007 $0.003 fallen by 57.14%
$5 Change of Director's Interest Notice-Dr Charmaine Gittleson 20 Dec 2024 7:33PM $0.007 $0.003 fallen by 57.14%
$5 Notification of cessation of securities - PER 20 Dec 2024 7:25PM $0.007 $0.003 fallen by 57.14%
$5 Change in substantial holding 19 Dec 2024 4:48PM $0.007 $0.003 fallen by 57.14%
$5 Topline Six-Month Results From Phase IIb Study of Avicursen 18 Dec 2024 9:25AM $0.059 $0.003 fallen by 94.92%

76 - 100 of 178 results

Page 4 of 8

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.